Trade Names:Lexxel- Extended-release tablets enalapril maleate 5 mg/felodipine 2.5 mg- Extended-release tablets enalapril maleate 5 mg/felodipine 5 mg
The 2 components have complementary antihypertensive actions. Enalapril suppresses the renin-angiotension-aldosterone system. Felodipine dihydropyridine calcium channel blocker produces peripheral vasodilation.
Not indicated for initial treatment of hypertension.
History of angioedema.
PO 1 tablet every day for patients whose BP is not adequately controlled with felodipine or enalapril monotherapy. If inadequate BP control persists beyond 1 to 2 wk, increase to 2 tablets/day.
Store tablets at controlled room temperature (59° to 86°F). Protect from moisture and light.
Enalapril may increase risk of hypersensitivity.
AntacidsEnalapril bioavailability may be decreased. Separate administration times by 1 to 2 h.
BarbituratesEffects of felodipine may be decreased.
CapsaicinEnalapril-induced cough may be exacerbated.
CarbamazepinePlasma levels of felodipine may be decreased, reducing effect.
CYP3A4 inhibitors (eg, erythromycin)Increased effect of felodipine.
DiureticsExcessive reduction in BP may occur.
FoodEffects of felodipine may increase if given with grapefruit juice.
HydantoinsSerum felodipine levels may be decreased, reducing effects.
IndomethacinHypotensive effects may be reduced, especially in low-renin or volume-dependent hypertensive patients.
LithiumIncreased lithium levels and symptoms of lithium toxicity may occur.
PhenothiazineEnalapril may increase pharmacological effect of phenothiazines.
Potassium preparations, potassium-sparing diureticsEnalapril may increase serum potassium levels.
RifampinPharmacologic effects of enalapril may be decreased.
None well documented.
Peripheral edema (4%); angina; arrhythmias; AV block; chest pain; hypotension; MI; orthostatic hypotension; palpitation; syncope; tachycardia; vasculitis.
Headache (10%); dizziness (4%); asthenia, fatigue (2%); anxiety; insomnia; irritability; lightheadedness; nervousness; paresthesias; psychiatric disturbances; somnolence; vertigo.
Flushing (2%); pruritus; rash.
Abdominal discomfort; constipation; cramps; diarrhea; dry mouth; dyspepsia; flatulence; nausea; thirst; vomiting.
Micturition disorders; sexual difficulties; UTI.
Agranulocytosis; decreased hemoglobin and hematocrit; eosinophilia; epistaxis; neutropenia; pancytopenia; thrombocytopenia.
Hepatic failure.
Cough (2%); bronchitis; dyspnea; nasal or chest congestion; pharyngitis; respiratory infections; rhinitis; shortness of breath; sinusitis; sneezing; wheezing.
Arthralgia; arthritis; fever; gingival hyperplasia; hyperkalemia; muscle cramps; myalgia; pain; inflammation.
Category C (first trimester); Category D (second and third trimesters).
Secreted into breast milk.
Safety and efficacy have not been determined.
May have greater hypotensive effects and increased risk of peripheral edema with higher doses.
Reduce dose and give less frequently. Dose reduction or discontinuation may be necessary. Monitor renal function during first few weeks of therapy and adjust dosage.
Use with caution in patients with hepatic function impairment or reduced hepatic blood flow.
Angioedema may occur; use is contraindicated in patients with history of angioedema.
Use with caution.
Use felodipine with caution. Transient hypotension may occur.
Chronic dry cough may occur during treatment; higher incidence in women.
Neutropenia and agranulocytosis have occurred; risk appears greater with renal dysfunction and collagen vascular disease; monitor WBC counts frequently.
During major surgery or anesthesia, with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be caused by this mechanism, it can be corrected by volume expansion.
Abrupt withdrawal of calcium channel blockers may cause increased frequency and duration of angina. Taper dose gradually.